IMMEDIATELY place the ondansetron orally disintegrating tablet on top of the tongue where it will dissolve in seconds, then swallow with saliva. REPORTA UN EFECTO SECUNDARIO Administration with liquid is not necessary.Ondansetron Orally Disintegrating Tablets, USP are available containing 4 mg or 8 mg of ondansetron, USP.Ondansetron orally disintegrating tablets are contraindicated in patients:Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT Electrocardiogram (ECG) changes including QT interval prolongation have been seen in patients receiving ondansetron. También se utiliza para prevenir y tratar náuseas y vómitos después de la cirugía. ondansetron: dosis, para que sirve (indicaciones), efectos secundarios, ... a menos que el beneficio esperado para la paciente supere cualquier riesgo para el feto. Treatment response was based on the total number of emetic episodes over the 3-day trial period. Sáltese la dosis que dejó de tomar si ya casi es hora para la siguiente dosis. 8 mg; I.H. REPORTA SU EFECTIVIDAD Therefore, do not exceed a total daily dose of 8 mg in patients with severe hepatic impairment (Child-Pugh score of 10 or greater) No dosage adjustment is recommended for patients with any degree of renal impairment (mild, moderate, or severe). Use of ondansetron in these age-groups is supported by evidence from adequate and well-controlled studies of ondansetron in adults with additional data from 3 open-label, uncontrolled, non-U.S. trials in 182 pediatric patients aged 4 to 18 years with cancer who were given a variety of cisplatin or noncisplatin regimens Additional information on the use of ondansetron in pediatric patients may be found in ondansetron injection prescribing information.The safety and effectiveness of orally administered ondansetron have not been established in pediatric patients for:Of the total number of subjects enrolled in cancer chemotherapy-induced and postoperative nausea and vomiting in U.S.- and foreign-controlled clinical trials, for which there were subgroup analyses, 938 (19%) were aged 65 years and older.No overall differences in safety or effectiveness were observed between subjects 65 years of age and older and younger subjects. tanto, que las madres en periodo de lactancia no amamanten a los niños si están tomando este medicamento.No hay experiencia con este medicamento en la prevención y tratamiento de náuseas y vómitos postoperatorios en niños menores de 2 años.Consulte a su médico o farmacéutico antes de utilizar cualquier medicamento. Select one or more newsletters to continue. médico o farmacéutico o llame al Servicio de Información Toxicológica de su país o acuda al servicio de urgencias del hospital más próximo. No empuje la tableta a través del papel porque podría destruirla. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Laryngospasm, shock, and cardiopulmonary arrest have occurred during allergic reactions in patients receiving injectable ondansetron.Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small trials indicate that when used together, ondansetron may increase patient-controlled administration of tramadol. A causal relationship to therapy with ondansetron was unclear in many cases.The most common adverse reactions reported in greater than or equal to 4% of 300 adults receiving a single 24 mg dose of ondansetron orally in 2 trials for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy (cisplatin greater than or equal to 50 mg/m The most common adverse reactions reported in 4 trials in adults for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy (primarily cyclophosphamide-based regimens) are shown in Table 3.Liver failure and death has been reported in cancer patients receiving concurrent medications, including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. In these trial(s), patients were receiving multiple concomitant perioperative and postoperative medications in both treatment groups.In a crossover study with 25 subjects, headache was reported in 6 subjects administered ondansetron orally disintegrating tablets with water (24%) as compared with 2 subjects administered ondansetron orally disintegrating tablets without water (8%).The following adverse reactions have been identified during post-approval use of ondansetron. Su médico ha ponderado, antes de prescribírselo, ambos extremos. Siga sus instrucciones con preferencia a las indicadas en esta página web, que pueden ser diferentes. Guarde la medicina Tome la dosis que dejó de tomar tan pronto se acuerde. Ondansetron 8 mg three times daily is not a recommended regimen for the treatment of moderately emetogenic chemotherapy Treatment response was based on the total number of emetic episodes over the 3-day trial period.